MGI celebrates the inauguration of its new state-of-the-art demonstration laboratory in Japan

TOKYO, September 9, 2022 /PRNewswire/ — MGI Tech Co., Ltd. (MGI), a global life sciences leader and innovator, today announced the first day of its IPO in China the inauguration of a new demonstration laboratory in Tokyo, Japanimproving the experience of Japanese customers.

MGI expanded the operations of its sub-subsidiary, MGI Tech Japan Co., Ltd., by establishment of premises office, setting up a warehouse and now building an experience center in the new MGI Japan Demonstration Lab (Demo Lab) to serve local customers by accessing cutting-edge technology and innovative new products.

At the Demo Lab, MGI staff will work closely with local researchers, technology providers, service partners, and genomics community partners to provide technical evaluations, product testing, workflow validation clinical, new technology proof-of-concept programs, plus other technical support, service, and troubleshooting.

“Since the beginning of our activity in Japanwe have emphasized the importance of serving the Japanese community with our local presence, local talents and local collaborations with customers and partners such as RIKEN,” said Dr. Roy Tan, Managing Director of MGI Asia-Pacific. “Today, following breakthroughs in the US and European markets with our innovative technologies, we are renewing this commitment and plan to establish long-term growth with Japanese scientists and customers through the Demo Lab.”

“By better understanding the latest genomic needs of Japan, by providing early access to products and facilitating collaborative activities to give back to local communities, we believe we can truly advance science, offer the world the right of another choice, and achieve our vision of “Leading the innovation in the life sciences”. With that, I am extremely happy to launch the new DNBSEQ-G99* sequencer in Japan today and grant rapid access to this priority market,” added Dr. Tan.

Based on MGI’s proprietary DNBSEQMT technology*, DNBSEQ-G99* adapts a new patented triangular pattern array technology that is first deployed on MGI sequencing cells for faster biochemical reactions and higher density in this highly integrated fluid system. At the same time, it has built-in computer modules and an integrated cartridge, enabling more integrated and efficient data analysis, while ensuring simple and easy sequencing operation. The DNBSEQ-G99* is capable of running the PE150 in 12 hours with a daily throughput of 96 GB in its dual-cell mode of operation. It provides a range of read lengths including SE100, PE50, PE100, PE150 as well as SE400 and PE300 in the future.

Spanning over 200 square meters, the Demo Lab is equipped with MGI’s latest product portfolio, including sequencers such as DNBSEQ-T7*, DNBSEQ-G400* and DNBSEQ-G50*, as well as automation such as MGISP-NE32, MGISP-Smart8, MGISP-960 and MGISP-100 for DNA/RNA extraction, liquid handling, sequencing library preparation, etc. The suite of sequencing products supports a wide range of applications, such as WGS, WES, RNA-Seq, small RNA sequencing, single cell sequencing, spatial genomics and more. The recent launch of the PE300 sequencing capability has also enabled 16S metagenomic sequencing.

To fulfill its commitment to lead the life sciences through innovation, MGI APAC established the MGI Agriculture Genome Grant earlier this year to foster innovation and collaboration with research excellence and give back to the community. Two separate Japanese research groups from Shinshu University and The University of Tokyo of Agriculture and Technology are among the winners. With the new demonstration lab, MGI looks forward to enabling the localization of these research collaborations, empowering customers and partners, and further supporting the advancement of genomics in Japan.

About MGI

MGI Tech Co.Ltd. (MGI), headquartered in Shenzhen, is committed to creating foundational tools and technologies to lead the life sciences through intelligent innovation. Based on its proprietary technology, MGI focuses on the research and development, production and sales of sequencing instruments, reagents and related products to support life science research, agriculture, precision medicine and healthcare. MGI is a leading producer of high-throughput* clinical gene sequencers, and its multi-omics platforms include gene sequencing*, medical imaging and laboratory automation. MGI’s mission is to develop and promote advanced life science tools for future healthcare. For more information, visit the MGI website or contact us at TwitterLinkedIn or YouTube.

*Unless otherwise noted, StandardMPS and CoolMPS sequencing reagents and sequencers for use with these reagents are not available in Germany, SpainUK, hong kong, Sweden, Belgium, Italy, Finland, Czech Republic, Swiss, Portugal, Austria and Romania. No purchase orders for StandardMPS products will be accepted within the UNITED STATES until after January 1, 2023.

Source: MGI Tech Co., Ltd.